PTCT
Income statement / Annual
Last year (2024), PTC Therapeutics, Inc.'s total revenue was $806.78 M,
a decrease of 13.97% from the previous year.
In 2024, PTC Therapeutics, Inc.'s net income was -$363.30 M.
See PTC Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$806.78 M |
$937.82 M |
$698.80 M |
$538.59 M |
$380.77 M |
$306.98 M |
$264.73 M |
$194.39 M |
$82.71 M |
$36.77 M |
| Cost of Revenue |
$0.00
|
$65.49 M
|
$44.68 M
|
$32.33 M
|
$18.94 M
|
$12.14 M
|
$12.67 M
|
$4.58 M
|
$117.63 M
|
$121.82 M
|
| Gross Profit |
$806.78 M
|
$872.34 M
|
$654.12 M
|
$506.27 M
|
$361.82 M
|
$294.85 M
|
$252.06 M
|
$189.82 M
|
-$34.93 M
|
-$85.05 M
|
| Gross Profit Ratio |
1
|
0.93
|
0.94
|
0.94
|
0.95
|
0.96
|
0.95
|
0.98
|
-0.42
|
-2.31
|
| Research and Development Expenses |
$534.48 M
|
$666.56 M
|
$651.50 M
|
$540.68 M
|
$477.64 M
|
$257.45 M
|
$171.98 M
|
$117.46 M
|
$117.63 M
|
$121.82 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$153.55 M
|
$121.27 M
|
$97.13 M
|
$82.08 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$300.91 M
|
$332.54 M
|
$326.00 M
|
$285.77 M
|
$245.16 M
|
$202.54 M
|
$153.55 M
|
$121.27 M
|
$97.13 M
|
$82.08 M
|
| Other Expenses |
$273.96 M
|
$0.00
|
$116.55 M
|
$54.75 M
|
$36.89 M
|
$27.65 M
|
$129,000.00
|
-$1.28 M
|
-$1.21 M
|
-$465,000.00
|
| Operating Expenses |
$1.11 B
|
$1.31 B
|
$1.09 B
|
$881.21 M
|
$759.70 M
|
$487.64 M
|
$348.41 M
|
$254.11 M
|
$214.76 M
|
$203.90 M
|
| Cost And Expenses |
$1.11 B
|
$1.29 B
|
$1.14 B
|
$913.54 M
|
$778.64 M
|
$499.78 M
|
$361.08 M
|
$258.68 M
|
$214.76 M
|
$203.90 M
|
| Interest Income |
$0.00
|
$0.00
|
$90.87 M
|
$86.02 M
|
$56.35 M
|
$12.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$166.99 M
|
$129.18 M
|
$90.87 M
|
$86.02 M
|
$56.35 M
|
$12.49 M
|
$12.55 M
|
$12.09 M
|
$8.28 M
|
$2.37 M
|
| Depreciation & Amortization |
$75.66 M
|
$236.59 M
|
$128.84 M
|
$71.52 M
|
$49.58 M
|
$36.06 M
|
$26.09 M
|
$17.68 M
|
$3.29 M
|
$2.88 M
|
| EBITDA |
-$120.46 M |
-$330.34 M |
-$367.78 M |
-$374.44 M |
-$297.00 M |
-$191.38 M |
-$89.47 M |
-$46.61 M |
-$128.77 M |
-$164.25 M |
| EBITDA Ratio |
-0.15
|
-0.35
|
-0.53
|
-0.7
|
-0.6
|
-0.38
|
-0.2
|
-0.25
|
-1.6
|
-4.55
|
| Operating Income Ratio |
-0.38
|
-0.37
|
-0.63
|
-0.7
|
-1.04
|
-0.63
|
-0.44
|
-0.33
|
-1.6
|
-4.55
|
| Total Other Income/Expenses Net |
-$60.55 M
|
-$346.71 M
|
-$147.56 M
|
-$143.40 M
|
-$59.36 M
|
-$47.13 M
|
-$12.43 M
|
-$13.37 M
|
-$9.48 M
|
-$2.83 M
|
| Income Before Tax |
-$363.12 M
|
-$696.11 M
|
-$587.49 M
|
-$518.34 M
|
-$402.93 M
|
-$239.93 M
|
-$128.11 M
|
-$77.67 M
|
-$141.54 M
|
-$169.96 M
|
| Income Before Tax Ratio |
-0.45
|
-0.74
|
-0.84
|
-0.96
|
-1.06
|
-0.78
|
-0.48
|
-0.4
|
-1.71
|
-4.62
|
| Income Tax Expense |
$176,000.00
|
-$69.51 M
|
-$28.47 M
|
$5.56 M
|
$35.23 M
|
$11.65 M
|
-$29,000.00
|
$1.34 M
|
$569,000.00
|
$485,000.00
|
| Net Income |
-$363.30 M
|
-$626.60 M
|
-$559.02 M
|
-$523.90 M
|
-$438.16 M
|
-$251.58 M
|
-$128.08 M
|
-$79.00 M
|
-$142.11 M
|
-$170.45 M
|
| Net Income Ratio |
-0.45
|
-0.67
|
-0.8
|
-0.97
|
-1.15
|
-0.82
|
-0.48
|
-0.41
|
-1.72
|
-4.64
|
| EPS |
-4.73 |
-8.37 |
-7.79 |
-7.43 |
-6.64 |
-4.27 |
-2.75 |
-2.02 |
-4.17 |
-5.07 |
| EPS Diluted |
-4.73 |
-8.37 |
-7.79 |
-7.43 |
-6.64 |
-4.27 |
-2.75 |
-2.02 |
-4.17 |
-5.07 |
| Weighted Average Shares Out |
$76.85 M
|
$74.84 M
|
$71.73 M
|
$70.47 M
|
$66.03 M
|
$58.86 M
|
$46.58 M
|
$39.11 M
|
$34.04 M
|
$33.62 M
|
| Weighted Average Shares Out Diluted |
$76.85 M
|
$74.84 M
|
$71.73 M
|
$70.47 M
|
$66.03 M
|
$58.86 M
|
$46.58 M
|
$39.18 M
|
$34.04 M
|
$33.63 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
